CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Ergot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist
Updated · Methodology
Mechanism
Cobicistat boosts atazanavir or darunavir and is also part of combination tablets with these drugs or with elvitegravir (summaries of product characteristics, SmPCs, of cobicistat and its combinations, European Medicines Agency, EMA). Cobicistat is a strong CYP3A inhibitor. Drugs that CYP3A metabolises extensively and that undergo high first-pass metabolism show the largest rises in exposure with it (cobicistat SmPC, EMA). The same SmPC lists dihydroergotamine among drugs whose clearance depends heavily on CYP3A and whose high levels carry a risk of serious or life-threatening reactions (cobicistat SmPC, EMA). CYP3A4 inhibition raises dihydroergotamine blood levels and the risk of vasospasm with ischaemia of the brain and limbs. With the strong inhibitor itraconazole, exposure to dihydroergotamine itself rose by 14–19%, while exposure to its active metabolite, an equally potent venoconstrictor, rose about 3- to 4-fold (dihydroergotamine labels, US Food and Drug Administration, FDA). The documents report no study of this pair. The darunavir/cobicistat SmPC bases the expected rise in ergot levels on theoretical grounds (EMA). The US cobicistat label links the combination to acute ergot toxicity with peripheral vasospasm and ischaemia of the limbs and other tissues (cobicistat label, FDA).
Symptoms
With excess dihydroergotamine, the muscles ache, the fingers and toes become numb, cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine labels, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, and coldness or colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine labels, FDA). Myocardial and colonic ischaemia have also been reported. Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine labels, FDA).
Management
The combination is contraindicated. Dihydroergotamine is on the contraindication list of the EU summaries of product characteristics (SmPCs) for cobicistat and its combinations with elvitegravir, atazanavir and darunavir (SmPCs of cobicistat and its combinations, European Medicines Agency, EMA). The US cobicistat label contraindicates it when cobicistat is taken with either atazanavir or darunavir (cobicistat label, US Food and Drug Administration, FDA). The dihydroergotamine labels, for their part, contraindicate strong CYP3A4 inhibitors and give human immunodeficiency virus (HIV) protease inhibitors as examples (dihydroergotamine labels, FDA). The cobicistat SmPC describes cobicistat as a strong CYP3A inhibitor (cobicistat SmPC, EMA). Dihydroergotamine is not in the Spanish medicines register. Review all of the patient's medicines for interactions before and during cobicistat treatment, and monitor for adverse reactions to them (cobicistat label, FDA). Tell the patient to stop dihydroergotamine and get emergency help at once if they develop cramping and pain in the legs, numbness, coldness or colour change in the legs, slurred speech or sudden weakness (dihydroergotamine labels, FDA). If both drugs have nevertheless been taken and signs of vasospasm appear, stop dihydroergotamine at once (dihydroergotamine labels, FDA). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist. Warm the affected area, give vasodilators and provide nursing care to prevent tissue damage (dihydroergotamine labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5